Improvement in vertigo · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in vertigo · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IBS symptoms · people with IBS
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Topiramate showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight Average endpoint/change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
It is very uncertain whether metformin changes leaving the study early: for any reason compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Metformin showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Depression response (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
It is very uncertain whether antidepressants changes depression response (acute phase, 5 ≤ 12 weeks) compared with any other pharmacological intervention (very low certainty).
1 finding from 1 review
RR 0.98 [0.76, 1.27]
Studies not reported
Very low
Depression remission · women of any age, with PND up to 12 months
It is very uncertain whether antidepressants changes depression remission (acute phase, 5 ≤ 12 weeks) compared with any other pharmacological intervention (very low certainty).
2 findings from 1 review
RR 0.98 [0.68, 1.41]
Studies not reported
Very low
no estimate extracted
Studies not reported
Low
Adverse events · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression response (early phase, < 5 weeks) · women of any age, with PND up to 12 months
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Depression severity (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
1 finding from 1 review
no estimate extracted
Studies not reported
Very low